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Abstract
Elevated levels of the transcription factor c-myc are strongly associated with various cancers, and 
in particular B-cell lymphomas. While many of c-MYC’s functions have been elucidated, its effect 
on the presentation of antigen (Ag) through the HLA class II pathway has not previously been 
reported. This is an issue of considerable importance, given the low immunogenicity of many c-
MYC-positive tumors. We report here that increased c-MYC expression has a negative effect on 
the ability of B-cell lymphomas to functionally present Ags/peptides to CD4+ T cells. This defect 
was associated with alterations in the expression of distinct co-factors as well as interactions of 
antigenic peptides with class II molecules required for the presentation of class II-peptide 
complexes and T cell engagement. Using early passage Burkitt’s lymphoma (BL) tumors and 
transformed cells, we show that compared to B-lymphoblasts, BL cells express decreased levels of 
the class II editor HLA-DM, lysosomal thiol-reductase GILT, and a 47kDa enolase-like protein. 
Functional Ag presentation was partially restored in BL cells treated with a c-MYC inhibitor, 
demonstrating the impact of this oncogene on Ag recognition. This restoration of HLA class II-
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mediated Ag presentation in early passage BL tumors/cells was linked to enhanced HLA-DM 
expression and a concurrent decrease in HLA-DO in BL cells. Taken together, these results reveal 
c-MYC exerts suppressive effects at several critical checkpoints in Ag presentation which 
contribute to the immunoevasive properties of BL tumors.
Introduction
The c-MYC protein was first identified 30 years ago as a homologue of an avian retroviral 
oncogene (1). It is a transcription factor encoded by the MYC gene and boasts a target gene 
network encompassing approximately 15% of all known genes (2–4). The c-MYC protein 
belongs to the family of basic region helix-loop-helix/leucine zipper transcription factors 
and its activity is dependent on the formation of heterodimers with MAX, upon which the 
heterodimers bind to regions of DNA with the CACGTG sequence motif (E-boxes) (5–7). 
The transcriptional effects of c-myc are thought to be exerted primarily through the 
recruitment of transcriptional cofactors involved in RNA polymerase II function, as well as 
the recruitment of histone acetyl transferases, which acetylate lysine residues in histones and 
cause a more open structure of the chromatin allowing for increased transcription of target 
genes (8–10). To a lesser extent, c-myc exerts its functions on genes transcribed by RNA 
polymerases I and III, and may repress transcription through interactions with the Miz-1 
transcription factor (11). Overexpression of c-myc also controls genes with a wide array of 
functions, ranging from cell-cycle progression to differentiation to apoptosis (2, 12).
Transformation of cells by c-MYC protein involves numerous genes (9). Paradoxically, 
while c-MYC activity induces cell growth and differentiation, it also induces apoptosis. This 
is achieved through activation of the p53 tumor suppressor and inhibition of cyclin D1 as 
well as indirect suppression of anti-apoptotic BCL2 and induction of pro-apoptotic BAX and 
Bim (9, 13, 14). Since its discovery, c-myc has come to be recognized as one of the most 
commonly activated oncogenes in human cancers and is observed in virtually all 
malignancies (13, 15). c-MYC protein expression is implicated in the cancer-related deaths 
of approximately 100,000 people in the United States as well as millions worldwide every 
year (2, 15, 16). Among malignancies that have a known association with c-myc 
overexpression, Burkitt Lymphoma (BL) may be the most prominent. Indeed, 
overexpression of c-myc is a hallmark of BL and activation of c-myc by chromosomal 
translocation is considered diagnostic for this lymphoid malignancy. In BL, c-myc is 
translocated to an immunoglobulin locus, resulting in its constitutive expression and cell 
transformation. The most prominent of these translocations is t(8:14) which is observed in 
80% of BL, while t(8:22) and t(8:2) are observed with lesser frequencies (17, 18). These 
translocations are generated as accidents of antibody affinity maturation during the germinal 
center reaction through the action of activation-induced cytidine deaminase (AID) (19).
BL is a highly aggressive type of non-Hodgkin’s Lymphoma that occurs most frequently in 
tropical climates, with a distribution closely following that of holoendemic malaria (20). A 
sporadic form is observed in other parts of the world and a third form is found associated 
with HIV. Malaria and EBV, each alone or together, and HIV increase the risk of 
developing BL, presumably by polyclonal B cell stimulation including activation of AID 
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and by conferring anti-apoptotic functions to cells hit by the c-myc translocation, but the 
precise contribution remains to be defined (20–23). BL is typically treated effectively with 
aggressive chemotherapy in young patients, but inferior responses are observed in adults 
(especially the elderly) and immunodeficient patients (24). Additionally, older and 
immunodeficient patients are less tolerant of the aggressive chemotherapy required and 
show increased signs of treatment-associated toxicities. This gap in treatment for these 
patient groups highlights the need for exploration into improved treatment options which 
would display lower levels of toxicity. The most ideal treatments would harness the immune 
system of the individual to target malignant cells. In EBV-positive BL, EBNA-1 is 
expressed as the only viral protein and it poorly stimulates cytotoxic CD8+ T cells due to its 
low immunogenicity (25–29). As a result, CD8+ T cell responses to BL are weak and 
unsustained. While multiple defects in class I antigen presentation and immune escape have 
been reported (25–29), little is known about disruption of class II presentation by malignant 
tumors. However, effective tumor immune responses usually involve the stimulation and 
maintenance of tumor specific CD8+ HLA class I-restricted cytotoxic T cells (CTL) and 
tumor-specific CD4+ class II-restricted helper T cells (30–32). Several groups have also 
shown that HLA class II-restricted CD4+ CTL could be generated against BL as well as 
non-Hodgkins follicular lymphoma (FL) (33–36), suggesting the feasibility of using 
sufficient tumor specific CD4+ T cells to eliminate B-cell tumors. Most B-cell tumors, 
including BL, express class II molecules, could provide their own HLA class II Ag 
presentation and be targets for helper CD4+ T cells. Increased expression of c-MYC imparts 
reduced immunogenicity to BL cells by antagonizing the NF-κB and interferon pathways 
(28, 29). In EBV immortalized B-lymphoblastoid cell lines (B-LCL), c-MYC is expressed at 
low levels and these cells retain a highly immunogenic phenotype with blast formation 
observed during growth due to expression of LMP1 that activates the canonical as well as 
the non-canonical NF-κB pathway (37). However, if B-LCLs are transfected to express 
measurable c-MYC, tumor immunogenicity is greatly diminished and suspension growth is 
observed, which corresponds to the phenotypes of BL cell lines (29, 38). Clearly, the 
expression of c-MYC plays an important role in reducing the immunogenicity of BL.
Although c-MYC expression has been described to have multiple effects on malignant cells, 
the role it plays in HLA class II-mediated Ag presentation and immune recognition has not 
been reported. Recently, it has been shown that the expression of invariant chain (Ii) 
regulates the repertoire of tumor peptides presented by class II-positive tumor cells (39). The 
absence of Ii has also been shown to facilitate CD4+ T cell responses (39, 40). Thus, 
expression levels of the components of the class II pathway such as Ii, class II-associated 
invariant chain peptide (CLIP), and HLA-DM/DO molecules in B-cells as well as tumors 
may modulate immune recognition. Here, studies revealed that cells expressing high levels 
of c-MYC are poor stimulators of CD4+ T cells. c-MYC expression in these cells was tied to 
alterations in the expression of HLA-DM, the lysosomal thiol reductase (GILT), and a 
47kDa enolase-like protein. We further show that treatment of c-MYC-overexpressing cells 
with a c-MYC inhibitor led to decreased c-MYC expression, restoration of HLA-DM 
concurrent with decreased HLA-DO molecules, and partial restoration of class II-mediated 
Ag presentation. Together these results strongly suggest that c-MYC expression plays a key 
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role in immune evasion via altering HLA class II Ag presentation, and opens the door for 
novel therapeutics to reverse this deficiency in BL.
Materials and Methods
Cell lines and tumors
Human B-lymphoblastoid cell lines (B-LCL) Frev, Priess and 6.16 were cultured in IMDM 
(Mediatech, Manassas, VA) supplemented with 10% bovine growth serum (Hyclone, Logan, 
UT), and 50U/ml penicillin and 50μg/ml streptomycin (Mediatech) (41). The B-LCL 
EREB2-5 (42) was cultured in RPMI 1640 (Mediatech) supplemented with 10% fetal bovine 
serum (Invitrogen, Carlsbad, CA), 50U/ml penicillin/50μg/ml streptomycin and 2μM 
estrogen, 1% L-glutamine (Mediatech) and 50μM β-mercaptoethanol (Invitrogen) (43, 44). 
Human BL (Ramos) and BL-like cell lines (Nalm-6, A1 and P493-6) were maintained in 
complete RPMI-1640 supplemented with 10% fetal bovine serum, 50U/ml penicillin and 
50μg/ml streptomycin, and 1% L-glutamine (41, 45, 46). The wild-type B-LCL, Frev, 
constitutively expresses HLA-DR4 molecules. Priess cells are homozygous for the 
expression of HLA-DR4 (DRA*0101, DRB*0401) molecules. The P493-6 cell line was 
cultured in the presence of 2μM estrogen with or without 5μg/ml tetracycline to control 
expression of EBNA-2 and c-myc (P493-6.DR4.est and P493-6.DR4.est.tet, respectively) 
(38). EREB2-5, 6.16, Nalm-6, Ramos, A1, and P493-6 cell lines were retrovirally 
transduced with a common allele of HLA-DR4 (DRB1*0401) with linked drug selection 
markers for hygromycin or histidinol resistance (47) to generate EREB2-5.DR4, 6.16.DR4, 
Nalm-6.DR4, Ramos.DR4, A1.DR4 and P-493-6.DR4 cell lines. 6.16.DR4 cells were 
further transfected with DMα and DMβ for constitutive expression of HLA-DM molecules 
to generate 6.16.DR4.DM (41). Frev cells were also transfected with an empty vector or c-
myc to generate Frev.vec and Frev.c-myc cell lines.
T cell hybridomas 2.18a and 1.21 recognize Igκ residues 188-203 and 145-159, respectively, 
and were generated by immunization of DR4-transgenic mice as described previously (44, 
48). The T cell hybridoma line 17.9 (generously provided by D. Zaller, Merck Research 
Laboratories, Rahway, NJ) responds to human serum albumin (HSA) residue 64-76K (49), 
was cultured in RPMI 1640 with 10% FBS, 50U/ml penicillin/50μg/ml streptomycin and 
50μM β-mercaptoethanol (Invitrogen). Institutional approval (HR#17159) for the use of 
human tissue and tumor samples was obtained. Lymph nodes and blood samples were 
obtained from two lymphoma patients (TB#2952, TB#7378) through our Hollings Cancer 
Center Tissue Bank (Medical University of South Carolina, Charleston, USA). TB#2952 
and TB#7378 tumors are EBV-positive as analyzed by the Biorepository & Tissue Analysis 
Shared Resource of the Hollings Cancer Center at MUSC. Blood samples were also 
obtained from two healthy individuals with written consent (approved protocol HR#17159). 
Of these (C#16, #C101) and of two tumors (TB#2952, TB#7378), B-cells were isolated 
using a B-Cell Isolation Kit II (#130-091-151). A portion of B-cells from a healthy 
individual (#C16) and from a BL tumor (TB#2952) were then infected in vitro with EBV 
(41), and transfected with HLA-DR4 (DRB1*0401) as described (43). These DR4-
expressing early passage cells were used in the functional class II Ag presentation and T cell 
recognition assays. Cells were cultured in RPMI 1640 with 10% FBS, 50U/ml penicillin/
God et al. Page 4
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
50μg/ml streptomycin and 50μM β-mercaptoethanol (Invitrogen). An explanatory table was 
also included listing the type and source of the cells and peptide specificity for the T cell 
hybridomas (Table I).
Antigens and peptides
Human serum albumin (HSA) and human IgG kappa (Igκ) were purchased from Sigma (St. 
Louis, MO). HSA64-76K (sequence: VKLVNEVTEFAKTK), human Igκ immunodominant 
κ188-203 (sequence: KHKVYACEVTHQGLSS, referred to as κI), subdominant κ145-159 
(sequence: KVQWKVDNALQSGNS, referred to as κII) peptides were produced using 
Fmoc technology and an Applied Biosystems Synthesizer as described (44, 47, 49–51). The 
Igκ188-203 and Igκ145-159 peptides were labeled as indicated at the α amino termini by the 
sequential addition of 2 molecules of Fmoc-6-aminohexanoic acid followed by a single 
biotin to yield the sequence biotin-aminohexanoic acid-aminohexanoic acid-peptide. 
Reverse phase HPLC purification and mass spectrometry were used to analyze the peptide 
and showed a peptide purity > 99%. These DR4-restricted peptides were dissolved in PBS 
and stored at −20°C until use.
Antigen presentation assays
B-LCL and BL cells were incubated with the whole Ags (Igκ or HSA), or its synthetic 
epitopes (Igκ188-203, Igκ145-159 or HSA64-76K) for 4h at 37°C in the appropriate cell culture 
media (43, 44, 51, 52). Cells were then washed and co-cultured with the T cell hybridomas 
(12.18a and 1.21 cells recognize Igκ188-203 and Igκ145-159 peptides respectively; 17.9 cells 
recognizes HSA64-76K peptide) for 24h at 37°C. In separate assays, P493-6.DR4 cells were 
left untreated or treated for 24h with 50μM of the c-MYC inhibitor 10058-F4 (Calbiochem, 
Billerica, MA). Peptides and Ags were added for the last 4h, and the cells were washed and 
co-cultured with the appropriate peptide specific T cell hybridomas for 24h. For endogenous 
Ag presentation assay, cells (Priess EREB2-5.DR4, A1.DR4 and P493-6.DR4) which 
innately express Igκ were cocultured with the appropriate epitope or peptide specific T cell 
hybridomas for 24h (47, 51, 53). For all assays, following co-culture with the T cell 
hybridoma, T cell production of IL-2 was quantitated by ELISA (52, 54). Assays were 
repeated in triplicate with standard error for triplicate samples within a single experiment 
being reported.
Western blot analysis
Cell lysates obtained from Frev.vec, Frev.c-myc, EREB2-5.DR4 and A1.DR4 were analyzed 
by Western blotting as previously described for expression of HLA-DR, Ii and HLA-DM 
with β-actin (Santa Cruz Biotechnology, Santa Cruz, CA) as a loading control (47, 55-57). 
Nuclear lysate from Frev.vec, Frev.c-myc, EREB2-5.DR4, A1.DR4, Priess, P493-6.DR4, 
P493-6.DR4.est.tet, 6.16.DR4.DM, Nalm-6.DR4, Ramos.DR4 were analyzed by Western 
blotting for expression of c-MYC (Santa Cruz Biotechnology), EBNA-1 and EBNA-2 (gift 
from Dr. Elisabeth Kremmer, Munich, Germany) with β-actin as the loading control. In 
separate assays, P493-6.DR4. were left untreated or treated for 24h with 50μM or 100μM of 
the c-MYC inhibitor 10058-F4. Following treatment, cells were harvested, nuclear lysate 
obtained, and analyzed by Western blotting for expression of c-MYC with β-actin as the 
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loading control. Densitometry was performed using a ChemiDoc XRS station (Bio-Rad, 
Hercules, CA) where the protein bands were analyzed using the Quantity One 4.6.3 software 
(Bio-Rad). Relative protein expression levels were stated as a ratio of specific proteins 
expressed/β-actin for each sample. Data are representative of at least three separate 
experiments.
Flow cytometric analysis
Frev, Frev.c-myc, EREB2-5.DR4, A1.DR4, P493-6.DR4, and P493-6.DR4.est/tet cells were 
stained with antibodies against HLA-DR (L243 antibody) and HLA-DR4 (359-F10 
antibody) followed by a secondary FITC conjugate (46, 50, 52). P493-6.DR4 and 
P493-6.DR4.est/tet cells were also stained with antibodies against CLIP (cer-CLIP 
antibody), Ii (Pin 1.1 antibody), HLA-DM (MAP1.1-DM antibody) and HLA-DO 
(Mags.DO5-FITC and isotypes were a gift from L. Denzin, Sloan-Kettering). P493-6.DR4 
cells treated with vehicle alone or c-MYC inhibitor 10058-F4 were also stained with 
antibodies and matched isotype controls for the detection of CLIP and HLA-DM molecules. 
Primary or early passage B cells and tumors were stained with appropriate antibodies as 
described above for the detection of HLA-DR, CLIP, HLA-DM and HLA-DO molecules. 
Samples were then analyzed on FACScan using CellQuest software (BD Biosciences, 
Mountain View, CA). Background fluorescence was evaluated using irrelevant isotype-
matched antibodies (NN4, IN-1) as described (46, 50, 52).
Peptide binding assay
Flow cytometric peptide binding assay was used to determine peptide binding to HLA-DR4 
molecules on P493-6.DR4+est/tet (c-myclow) and P493-6.DR4 (c-mychigh) cells using a 
modified method (58). Briefly, P493-6.DR4 (4×105) cells cultured under c-myc on/off 
conditions were washed twice with ice-cold PBS containing 1% BSA, and incubated with 
either vehicle alone or 40μM of biotin-labeled HSA64-76K peptide for overnight separately at 
4°C and 37°C. Cells were washed and stained with FITC-conjugated streptavidin (Santa 
Cruz, sc-2865) for 30min at 4°C, and analyzed by FACScan using CellQuest software (BD 
Biosciences).
Protein extraction and digestion
Acid eluted surface proteins were obtained from P493-6.DR4 and P493-6.DR4.est.tet cells, 
run on a non-reducing gel, and stained with Coomassie blue (41). Gel plugs were excised 
and placed in an eppendorf tube. Each plug was washed with 50mM ammonium bicarbonate 
and de-stained using 25mM ammonium bicarbonate in 50% acetonitrile. The plugs were 
dehydrated with 100% acetonitrile, and dried in a speedvac. Each gel plug was covered with 
Proteomics Grade Trypsin (Sigma) and incubated at 37°C overnight. The supernatant was 
collected in a clean dry eppendorf tube. Peptides were further extracted with one wash of 
25mM ammonium bicarbonate and three washes of 5% formic acid and 50% acetonitrile. 
The supernatant was collected and pooled after each wash then dried down in a speedvac to 
~1μL. Prior to analysis, the samples were reconstituted with 10μl of 0.1% trifluoroacetic 
acid. Samples were then concentrated with a C18 Ziptip (Millipore) and eluted with 0.1% 
TFA, 50% acetonitrile, and 7.0mg/mL α-cyano-4-hydroxycinnamic acid directly onto the 
MALDI target.
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MALDI-TOF/TOF mass spectrometry
After protein extraction, digestion and elution, the protein spots were dried completely, and 
the MALDI target plate was loaded into the Applied Biosystems 4800 Proteomics Analyzer 
(50). An external calibration was preformed prior to analyzing samples utilizing the 
manufacturer’s standards and protocols. Samples were analyzed in batch mode using 2000 
laser shots per spectrum. First, peptide mass maps were acquired over the m/z range of 800–
3500 in reflectron mode with a delayed extraction time optimized for m/z 2000 by averaging 
2000 scans to locate peaks of peptide origin. The next batch run performed MS-MS analyses 
to obtain sequence data on the 20 most abundant peaks from the MS analysis. Upon 
completion of the batch processing, the data was exported into the GPS Explorer data 
processing system for interpretation and identification. The MASCOT database-searching 
algorithm analyzed the data, and summarized the results in report format. Database searches 
were performed using 2 missed cleavages and one differential modification of methionine 
oxidation. The top 20 matches were reviewed prior to assigning confident protein 
identifications.
Statistical analysis
The data are expressed as the mean (±SD) and analyzed using Student’s t-test or one-way 
ANOVA, with p≤0.05 considered statistically significant. A nonparametric Wilcoxon Rank 
Sum test was also used when comparing band intensity obtained from densitometric analysis 
of distinct protein bands detected in western blotting of different cells.
RESULTS
Overexpression of c-MYC imparts a non-immunogenic BL phenotype to B-LCL
Although EBV-positive BL cells express EBV antigens (Ags), these cells are poorly 
recognized by HLA class I-restricted CD8+ T cells because of diminished viral epitope 
presentation via the HLA class I pathway. While the Ag specific lysis of tumors is 
predominantly a function of CD8+ T cells, HLA-class II-restricted CD4+ T cell function is 
crucial in maintaining sustained immune responses to tumors (59–61). Given the high levels 
of c-MYC expression associated with BL, the effect of c-MYC overexpression on HLA 
class II Ag presentation was examined. For these studies, several approaches were used to 
alter c-MYC levels in human B cell lines to parallel c-MYC expression in BL. The B-LCL 
Frev was transfected with either an empty vector (Frev.vec) or c-myc (Frev.c-myc). The 
EREB2-5 cell line was generated from primary human B-cells by co-infecting with an 
EBNA-2-deficient P3HR1 virus and recombinant EBV encoding an estrogen receptor 
EBNA-2 fusion protein, to generate a B-LCL whose proliferation is dependent on estrogen 
(62, 63). These cells were then further transfected for constitutive expression of c-myc to 
generate the A1 cell line, capable of proliferation in the absence of EBNA-2 (64). Both 
EREB2-5 and A1 were transduced for expression of a common HLA-DR4 allele. Whole cell 
lysates from these cells were analyzed by western blotting for expression of c-MYC, 
EBNA-1 and EBNA-2 proteins (Fig. 1A). Expression of c-MYC was clearly elevated in 
Frev.c-myc and A1.DR4 cell lines when compared to Frev.vec and EREB2-5.DR4, 
respectively. For reference, the B-LCL line Priess displays low c-MYC expression. EBNA-1 
is expressed at comparable levels in each cell line, while EBNA-2 expression is detected in 
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Frev.vec and EREB2-5.DR4 which carries a mutant form of EBNA-2, and to a much lesser 
extent in the c-MYC overexpressing cells. The c-MYC overexpressing cells (Frev.c-myc, 
A1.DR4) also switched from a B-LCL (Frev.vec, EREB2-5.DR4) growth pattern (blast 
formation) to a BL growth pattern (suspension) (Fig. 1B). Frev.vec, Frev.c-myc, 
EREB2-5.DR4 and A1.DR4 were then analyzed by flow cytometry for surface expression of 
HLA class II DR4 (Fig. 1C). Overexpression of c-MYC did not affect expression of surface 
HLA class II proteins as each cell was found to express comparable levels. The results 
shown in Fig. 1D indicate that c-MYC overexpressing cells display a reduced capacity to 
present HSA64-76K peptide to stimulate CD4+ T cells via the class II pathway.
Overexpression of c-MYC alters expression levels of HLA class II pathway components
Although c-MYC overexpression did not affect the surface expression of HLA class II 
proteins, it remained possible that the intracellular components of the class II pathway were 
affected thus disrupting CD4+ T cell recognition of BL cells. Frev.vec, Frev.c-myc, 
EREB2-5.DR4 and A1.DR4 whole cell lysates were analyzed by western blotting for 
expression levels of the class II pathway components HLA-DR, invariant chain (Ii), HLA-
DM, and a lysosomal thiol-reductase GILT (Fig. 2A and B). In parallel assays, the 
expression of cell surface HLA class II proteins was also analyzed (Fig. 2C). Expression 
levels of both intracellular and cell surface HLA-DR molecules remained unchanged or 
were minimally altered in the c-MYC low and c-MYC high cells. There was also no 
significant change observed for Ii protein expression as analyzed by the Wilcoxon Rank 
Sum test. However, HLA-DM and GILT proteins were significantly decreased in the c-
MYC-high cells as compared to c-MYC-low cells (p≤0.0022), suggesting possible 
implications for c-MYC-induced effects on HLA class II Ag presentation.
Overexpression of c-MYC disrupts Ag processing and presentation via the HLA class II 
pathway
To examine whether BL cells expressing high levels of c-myc have a diminished capacity 
for HLA class II-mediated Ag presentation, whole cell lysates were first obtained from the 
B-LCL 6.16.DR4.DM and two wild-type BL lines Nalm-6 and Ramos, and analyzed by 
western blotting for expression of c-MYC proteins (Fig. 3A). It was found that the BL lines 
Nalm-6.DR4 and Ramos.DR4 expressed significantly higher levels of c-MYC than the B-
LCL 6.16.DR4.DM. Each cell line was also incubated with either the whole Igκ Ag or 
synthetic version of κ epitope Igκ188-203 or Igκ145-159, followed by co-culture with the 
appropriate peptide-specific T cell hybridomas for 24h. Following incubation, the culture 
supernatant was analyzed by ELISA for IL-2 as a measure of T cell stimulation. 
Nalm-6.DR4 and Ramos.DR4 displayed a sharply diminished capacity to process and 
present Igκ-derived epitopes to stimulate CD4+ T cells when compared to 6.16.DR4.DM 
(Fig. 3B, left panel). Similarly, BL cells failed to functionally present synthetic peptides to 
activate CD4+ T cells via the HLA class II pathway (Fig. 3B, right panel).
To investigate whether both exogenous and endogenous routes of class II Ag presentation 
are disrupted in BL, a number of B-LCL (Priess.DR4, EREB2-5.DR4) and the c-MYC 
overexpressing counterpart of EREB2-5 cells (A1.DR4, BL-type cells) were analyzed by 
biochemical and functional assays. It is important to note that these cell lines innately 
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express endogenous Igκ Ag (data not shown). Western blot analysis of whole cell lysates 
from these cells showed that A1.DR4 cells expressed high levels of c-MYC whereas B-LCL 
and B-LCL-type cells expressed low levels of c-MYC proteins (Fig. 3C). To further 
investigate whether BL-type cells expressing high levels of c-myc have a diminished 
capacity for HLA class II-mediated exogenous Ag presentation, cells (Priess, EREB2-5.DR4 
and A1.DR4) were incubated with the whole Ag HSA for 4h (Fig. 3D, left panel). Cells 
were then washed and cocultured with the HSA64-76K epitope specific T cell hybridoma 
(17.9) for 24h. The production of IL-2 in the culture supernatant was quantitated by ELISA. 
Priess and EREB2-5.DR4 cells which express low levels of c-MYC efficiently presented 
HSA to CD4+ T cells, whereas high c-MYC-expressing A1.DR4 cells failed to optimally 
present the epitope to the same T cell hybridoma line.
To study the presentation of endogenous Ag, we used two T cell hybridoma lines 2.181 and 
1.21 which recognize κ188-203 and κ145-159 peptides respectively. We then cocultured Priess, 
EREB2-5.DR4 and A1.DR4 cells expressing endogenous Igκ with 2.181 and 1.21 T cell 
hybridomas followed by analysis of IL-2 production in the culture supernatant (Fig. 3D, 
right panel). A1.DR4 cells which express high levels of c-MYC failed to optimally present 
κ188-203 and κ145-159 epitopes to CD4+ T cells. These results strongly suggest that 
overexpression of c-MYC diminishes both exogenous and endogenous pathways of class II 
Ag presentation and CD4+ T cell recognition of c-myc overexpressing B-(BL-type) cells.
Inhibition of c-MYC expression partially restores CD4+ T cell recognition of BL-type cells 
via the HLA class II pathway
To determine the role of c-MYC in diminished class II presentation in BL cells, we 
employed the cell line P493-6.DR4, which can be reversibly shifted from an LCL-like 
phenotype (EBNA-2 on, exogenous c-myc off) to a BL-like phenotype (EBNA-2 off, c-myc 
on) by addition and withdrawal of estrogen plus tetracycline. P493-6 cells expressing DR4 
were cultured in the presence (c-myc off) or absence (c-myc on) of estrogen plus tetracycline 
(P493-6.DR4.est.tet versus P493-6.DR4 cells) (Fig. 4A). When cultured in the presence of 
estrogen plus tetracycline, c-MYC expression was markedly reduced (Fig. 4A). Cell surface 
HLA-DR and HLA-DR4 molecules were not significantly altered in P493-6.DR4 vs. 
P493-6.DR4.est.tet cells regardless of c-MYC expression (Fig. 4B). Cells grown under c-
myc on/off conditions were used in T cell assay to determine HLA class II-mediated Ag 
presentation capability. When cultured in the absence of tetracycline, P493-6.DR4 cells 
showed a sharply diminished capacity to stimulate T cells via HLA class II as compared to 
P493-6.DR4.est.tet cells cultured in the presence of estrogen plus tetracycline (Fig 4C). 
Because P493-6 cells express endogenous kappa antigen, P493-6.DR4 and 
P493-6.DR4.est.tet cell lines were cocultured with the κ188-203 and κ145-159 peptide specific 
T cells, followed by the quantitation of T cell production of IL-2 (Fig. 4D, right panel). 
Likewise, P493-6.DR4 showed a diminished capacity to present endogenous kappa epitopes 
to stimulate CD4+ T cells via the class II pathway. Taken together, both exogenous and 
endogenous presentation of class II-restricted peptides, were partially restored by 
downregulating c-MYC expression and shifting P493-6.DR4 cells towards an LCL-
phenotype by the addition of estrogen plus tetracycline.
God et al. Page 9
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
To investigate whether peptide binding to surface HLA-DR4 molecules was altered in c-
myc-high cells, we performed binding assays using biotin-labeled HSA peptide (HSA64-76K) 
and FITC-labeled avidin, followed by flow cytometric analysis. The binding of DR4-
restricted HSA peptide was very low at 4°C (Fig. 4E). But there was a trend that exogenous 
peptide loading by class II molecules was better in low-c-myc cells as compared to that 
observed in high-c-myc cells. This difference was more pronounced when the binding assay 
was performed in fixed cells at 37°C (Fig. 4F). The HSA peptide bound much better to DR4 
molecules on low-myc cells as compare to those of high-c-myc cells. These data suggest that 
the observed differential peptide binding to class II molecules could contribute to reduced 
peptide presentation and diminished T cell recognition of high-c-myc cells.
To further examine this finding, P493-6.DR4 cells were treated with the c-MYC inhibitor 
10058-F4, a small molecule inhibitor which decreases c-MYC expression in tumor cells 
(65). Whole cell lysates were obtained and analyzed by western blotting for expression of c-
MYC protein (Fig. 5A). A dose-dependent decrease in c-MYC expression was consistent 
with other reports that 10058-F4 treatment results in diminished cellular c-MYC expression. 
To determine whether inhibition of c-MYC can restore T cell recognition, P493-6.DR4 cells 
were treated with 50μM 10058-F4 for 24h, followed by incubation with the whole HSA for 
4h. Cells were also incubated with the synthetic version of HSA epitope (HSA64-76K) for 4h. 
After incubation, cells were washed and fixed with 1%paraformaldehyde, and co-cultured 
with the HSA epitope-specific T cell hybridoma 17.9 for 24h. The culture supernatant was 
then analyzed by ELISA for IL-2 as a measure of T cell stimulation (Fig. 5B, left panel). It 
was found that inhibition of c-MYC expression partially restored HLA class II-mediated Ag/
peptide presentation and CD4+ T cell recognition of BL-like P493-6 cells.
To determine whether inhibition of c-MYC can also restore the presentation of endogenous 
Ag, we employed A1.DR4 and P493-6.DR4 cells (both cell lines express high levels of c-
MYC) and cocultured with the κ188-203 epitope-specific T cell hybridoma line 2.181 for 24h. 
After incubation, T cell production of IL-2 production in the culture supernatant was 
quantitated by ELISA (Fig. 5B, right panel). It was found that inhibition of c-MYC protein 
by 10058-F4 significantly restored HLA class II-mediated presentation of endogenous Ag 
Igκ. Taken together, these data suggest that overexpression of c-MYC diminishes both 
exogenous and endogenous pathways of class II-restricted Ag presentation and CD4+ T cell 
recognition.
Flow cytometric analysis of P493-6 cells showed that c-MYC inhibitor 10058-F4 dose-
dependently reduced cell surface CLIP expression (29% vs. 13% and 29% vs. 7%) (Fig. 5C, 
upper panel), suggesting that c-MYC affects the number of peptide receptive class II 
complexes in the cell which may be linked to DM/DO. Further study using intracellular 
staining of DM/DO molecules confirmed that inhibition of c-MYC elevated DM molecules 
while down-regulating DO proteins (Fig. 5C, lower panel). These data suggest that the c-
MYC inhibitor may partially restore CD4+ T cell recognition by altering DM/DO protein 
ratio in BL-type cells, and that the disruption of c-MYC expression or function might hold 
potential in restoring CD4+ T cell recognition of BL.
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Inhibition of c-MYC down-regulates CLIP expression and reverses the ratio of HLA-DM/
HLA-DO molecules in c-MYC overexpressing BL-type P493-6 cells
Having established that treatment with the c-MYC inhibitor 10058-F4 was sufficient to 
partially restore class II-mediated antigen presentation in P493-6.DR4 cells, we sought to 
determine the mechanism how c-MYC impairs antigen presentation via the MHC class II 
pathway. To this end, P493-6.DR4 cells proliferating in the absence of estrogen plus 
tetracycline (c-myc program) were shifted back to a B-LCL phenotype by addition of 
estrogen plus tetracycline (38, 63), and then analyzed by flow cytometry for expression of 
cell surface CLIP and intracellular Ii, as well as DM/DO molecules. While no significant 
change was observed in Ii expression (93% vs. 94%), cell surface CLIP expression was 
markedly down-regulated (28% vs. 12%) (Fig. 6A). The shift from a BL-like (P493-6.DR4, 
A1.DR4) to a B-LCL-phenotype (P493-6.est.tet) led to a sharp increase in HLA-DM 
molecules (MFI: 194 vs. 801) (Fig. 6B). This increase in HLA-DM molecules was 
concurrent with a slight decrease in HLA-DO molecules (MFI: 274 vs. 158) and a 
significant increase (*p<0.001) in the DM/DO protein ratio (Fig. 6C). These data support the 
notion that the decrease in CD4+ T cell recognition of BL and BL-like P493-6 cells can be 
linked to alteration of the DM/DO protein ratio and increased surface CLIP expression as a 
result of overexpression of c-MYC protein.
Inhibition of c-MYC up-regulates a 47kDa enolase-like acid labile protein and regulates 
HLA class II-mediated Ag presentation
We have recently shown that a 47kDa enolase-like acid labile protein is highly expressed in 
B-LCL, and that this protein is nearly absent or expressed at a greatly reduced level in BL 
cells (41). This enolase-like protein facilitated B-T cell interactions by enhancing HLA class 
II peptide display to T cells. Studies were conducted to determine if c-MYC impacts the 
levels of this 47kDa protein. The 47kDa protein band was highly abundant in B-LCL type 
P493-6.DR4.est/tet cells as compared to BL type P493-6.DR4 cells (Fig. 6D). MALDI-
TOF/TOF mass spectrometric analysis confirmed that the 47kDa protein band was an alpha-
enolase 1-like molecule (Accession number 4503571; URL: ipi.HUMAN.V3.71). It is 
important to note that P493-6.DR4 cells express very high levels of c-MYC proteins relative 
to P493-6.DR4.est/tet cells, and that elevated c-MYC disrupts CD4+ T cell recognition of 
P493-6.DR4 cells (Fig. 4). In addition, BL-type P493-6.DR4 cells express lower levels of 
DM proteins as compared to B-LCL-type P493-6.DR4. est/tet cells (Fig. 6A and B). 
Collectively, these data suggest that the overexpression of c-MYC downregulates HLA-DM 
as well as the 47kDa enolase-like acid labile protein, leading to disruptions in immune 
recognition of BL.
High CLIP expression, a decrease in the DM/DO ratio, and impaired MHC class II antigen 
presentation are also observed in BL tumors ex vivo
To investigate whether high CLIP expression, a decrease in the DM/DO ratio, and impaired 
Ag presentation via the MHC class II pathway are also observed in primary BL TB#2952 
lymphoma was subjected ex vivo to western blotting and flow cytometry, and was compared 
with an early passage of an EBV transformed B-cell line of a healthy individual (C#16). 
Western blot analysis showed that TB#2952 expressed higher levels of c-MYC, but 
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equivalent intracellular DRβ proteins as compared with C#16 (Fig. 7A). T cell assay 
demonstrated that TB#2952 lymphoma which expressed higher levels of c-MYC failed to 
stimulate CD4+ T cells. Likewise, early passage TB#2952 cells that had been subjected to 
infection with EBV [TB#2952(+EBV)] had diminished capacity to stimulate CD4+ T cells 
as compared to EBV infected control cells [C#16(+EBV)] (Fig. 7B), indicating that in vitro 
EBV infection did not restore the deficiency in Ag presentation observed in BL tumor cells 
ex vivo.
Flow cytometric analyses of EBV-transformed early passage control C#16 and TB#2952 BL 
tumor cells showed comparable levels of cell surface HLA-DR molecules, while C#16 
expressed higher levels of HLA-DM and lower levels of DO and CLIP proteins (left panels 
of Fig. 7C). Exactly the same was found with another BL tumor (TB#7378) and control B 
cell pair of a healthy individual (C#101) (right panels of Fig. 7C). These data further support 
our findings that the alteration of DM/DO ratio and upregulation of CLIP cause reduced 
CD4+ T cell recognition of B-cell lymphoma.
DISCUSSION
In the 30 years since its discovery, the c-MYC protein has come to be recognized as one of 
the most commonly activated oncogenes in human cancers. As a transcription factor that 
controls up to 15% of all known cellular genes, the effects of c-MYC are wide ranging. 
Cellular functions and host defenses are frequently controlled by genes within the c-MYC 
target network including immune regulation (2). In spite of its far-reaching effects, c-MYC 
protein has never been reported to have an effect on the HLA class II pathway of Ag 
presentation. We report here for the first time that c-MYC overexpression results in 
decreased HLA class II-mediated immune recognition of BL.
The HLA class II pathway of Ag presentation is primarily involved in the presentation of 
exogenous Ags which have been internalized and degraded by antigen presenting cells 
(APCs). While HLA class I is expressed on every nucleated cell of the body, HLA class II 
expression is limited to the professional APCs: macrophages, dendritic cells and B-cells 
(66–69). In the class II pathway, extracellular Ags are internalized and degraded in 
endolysosomal compartments. Antigenic peptides are generated with the aid of cathepsins 
and GILT and deficiencies in these proteins lead to the production of peptides which are not 
optimal for class II-mediated Ag presentation (47, 56, 70, 71). HLA class II is synthesized in 
the endoplasmic reticulum (ER) lumen bound to Ii which occupies the binding groove to 
prevent inappropriate peptide binging and to aid in transporting class II through the Golgi 
and the endolysosomal compartments containing the antigenic peptides (72–74). Here, Ii is 
degraded by cathepsins leaving class II-associated invariant chain peptide (CLIP) occupying 
the class II binding groove (66, 68, 73, 75). HLA-DM then mediates the removal of CLIP 
and the binding of peptide to the class II binding groove (75–79). Removal of CLIP and 
class II peptide binding is partially modulated by the non-classical HLA-DO which inhibits 
the activity of HLA-DM. Shifts in the DM/DO ratio may cause an increase in destabilized 
cell-surface class II-CLIP complexes, thus impairing the HLA class II pathway of Ag 
presentation (78, 80–83). Most B-cell tumors including BL, express class II molecules, 
leading to the assumption that these cells should be ready targets for tumor-specific CD4+ T 
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cells. However, we have found that the presentation of nativeAg as well as peptides is 
influenced by elevated cellular c-MYC. Native Ag requires cellular internalization, 
processing and epitope loading by class II within endocytic compartments. To better 
understand this defect in class II presentation in cells with c-mychigh levels, we tested 
peptide binding to class II molecules at low temperature (4°C) in live cells and at 37°C in 
paraformaldehyde fixed cells. We found that the peptide binding to class II was reduced in 
c-mychigh cells as compared to c-myclow cells in each case. Loss of cellular DM can impact 
binding of exogenous peptides in multiple ways. Our previous reports demonstrated that 
cellular DM levels can impact peptide presentation as some peptides are endocytosed and 
bind intracellular class II molecules that may undergo DM editing (49, 57, 84). We similarly 
showed this was true of peptides which require reduction by the lysosomal-thiol reductase 
GILT (47, 85). Yet peptide binding studies here suggest that cellular c-MYC levels may also 
alter the conformation or peptide accessibility of class II molecules. Consistent with this, the 
conformation of class II molecules is known to be flexible, with loss of DM impacting class 
II structure and peptide loading (86). Inhibition of c-MYC also resulted in improved CD4+ 
T cell recognition of BL, suggesting that the alterations in peptide binding to class II 
molecules along with class II components DM/DO may be regulated by elevated c-MYC in 
tumor cells. Because the presentation of both exogenous and endogenous Ags were found to 
be disrupted in BL cells, c-MYC inhibitors could prove important in enhanced immune 
recognition of B-cell lymphomas.
We have shown here that overexpression of c-MYC leads to decreased class II-mediated 
immunogenicity in BL, by regulating the expression of key components of the HLA class II 
pathway. Elevation of c-MYC was found to cause a shift from the immunogenic B-LCL 
phenotype (growth with blast formation) to the non-immunogenic BL phenotype (growth as 
suspension cells) as reported previously (38). This shift in phenotype correlated with a 
decrease in HLA class II-mediated immunogenicity for several different peptide Ags. The 
cause of the c-MYC-associated decrease in immunogenicity does not seem to be linked to 
expression of class II proteins as both c-mychigh and c-myclow cells expressed comparable 
cell surface class II levels. Rather as shown here, c-MYC overexpression influences cellular 
expression of DM, DO and GILT, critical components which modulate the efficiency of 
class II Ag presentation. GILT reduces disulfide bonds in Ags which allows proteins to be 
unfolded and further processed by acidic proteases (56, 70, 71, 87). The importance of GILT 
for the class II pathway has been demonstrated in GILT−/− mice which are defective in their 
ability to process Ag, although they express normal levels of class II (47, 88, 89). It is 
plausible that the decreased immunogenicity observed in our c-mychigh cell lines is at least 
partially attributable to downregulation of the critical endolysosomal reductase GILT.
Secondly, we show that overexpression of c-MYC leads to decreased expression of the class 
II pathway component HLA-DM. As discussed above, HLA-DM mediates the removal of 
CLIP from the peptide binding groove as well as the binding of antigenic peptides. The 
functional importance of HLA-DM to class II-mediated Ag presentation was first recognized 
in B-LCL with mutations in DM which displayed impaired class II-peptide complex 
formation and defects in exogenous Ag presentation (68, 76, 80, 90). In keeping with this 
finding, we also demonstrate that expression of cell surface CLIP is increased in c-mychigh 
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cells. Given that one function of HLA-DM is to mediate the release of CLIP from the class 
II peptide binding groove, it is expected that in conditions of decreased HLA-DM 
expression, CLIP would remain bound to class II proteins and be expressed on the cell 
surface. Having demonstrated that overexpression of c-MYC was correlated with decreased 
class II-mediated Ag presentation and that this effect may be attributable to downregulation 
of GILT and HLA-DM, we next sought to determine if inhibition of c-MYC restored Ag 
presentation. Cells treated with the small molecule c-MYC inhibitor 10058-F4, partially 
restored class II-Ag presentation. When B-cells were treated with 10058-F4, cellular c-MYC 
levels dropped while a shift in the intracellular DM/DO ratio was observed. Treatment of B-
cells with 10058-F4 also resulted in decreased CLIP binding to class II molecules, a result 
consistent with DM editing of CLIP and the formation of increased numbers of peptide-
receptive class II molecules available to present exogenous and endogenous antigenic 
peptides. Further analyses with primary tumors confirmed that elevated DO and CLIP 
molecules disrupt CD4+ T cell recognition of BL.
It should be noted that inhibition of c-MYC was not sufficient to fully restore class II-
mediated Ag presentation. This is in keeping with our previously published (91) and current 
findings that a 47kDa α-enolase 1-like acid labile protein is nearly absent or expressed at a 
greatly reduced level in BL, and this deficiency may attenuate class II-mediated functional 
Ag presentation. The expression of α-enolase molecules has been shown to downregulate c-
MYC (92, 93); thus, the 47kDa α-enolase 1-like molecule may regulate c-myc as well as 
components of the HLA class II pathway to promote immune recognition of BL.
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CLIP class II-associated invariant chain peptide
DM HLA-DM
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GILT γ-IFN-inducible lysosomal thiol reductase
κ kappa
God et al. Page 14
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
References
1. Vennstrom B, Sheiness D, Zabielski J, Bishop JM. Isolation and characterization of c-myc, a 
cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol. 1982; 
42:773–779. [PubMed: 6284994] 
2. Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. 
Semin Cancer Biol. 2006; 16:253–264. [PubMed: 16904903] 
3. Lin Z, Yin Q, Flemington E. Identification of a negative regulatory element in the Epstein-Barr 
virus Zta transactivation domain that is regulated by the cell cycle control factors c-Myc and E2F1. 
J Virol. 2004; 78:11962–11971. [PubMed: 15479836] 
4. Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of Myc in the 
pathogenesis of Burkitt’s lymphoma? Semin Cancer Biol. 2009; 19:366–376. [PubMed: 19635566] 
5. Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011; 18:219–
228. [PubMed: 21490439] 
6. Larsson LG, Henriksson MA. The Yin and Yang functions of the Myc oncoprotein in cancer 
development and as targets for therapy. Exp Cell Res. 2010; 316:1429–1437. [PubMed: 20382143] 
7. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the 
transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000; 16:653–699. [PubMed: 
11031250] 
8. Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. Myc influences 
global chromatin structure. EMBO J. 2006; 25:2723–2734. [PubMed: 16724113] 
9. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8:976–990. [PubMed: 
19029958] 
10. Arabi A, Wu S, Ridderstrale K, Bierhoff H, Shiue C, Fatyol K, Fahlen S, Hydbring P, Soderberg 
O, Grummt I, Larsson LG, Wright AP. c-Myc associates with ribosomal DNA and activates RNA 
polymerase I transcription. Nat Cell Biol. 2005; 7:303–310. [PubMed: 15723053] 
11. Eilers M, Eisenman RN. Myc’s broad reach. Genes Dev. 2008; 22:2755–2766. [PubMed: 
18923074] 
12. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008; 27:6462–6472. 
[PubMed: 18955973] 
13. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging 
at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle. 
2011; 10:57–67. [PubMed: 21200143] 
14. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell 
leukemia. Proceedings of the National Academy of Sciences of the United States of America. 
2004; 101:6164–6169. [PubMed: 15079075] 
15. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. 
Oncogene. 1999; 18:3004–3016. [PubMed: 10378696] 
16. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K. Function of the c-
Myc oncogenic transcription factor. Exp Cell Res. 1999; 253:63–77. [PubMed: 10579912] 
17. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001; 
20:5595–5610. [PubMed: 11607812] 
18. Gerbitz A, Mautner J, Geltinger C, Hortnagel K, Christoph B, Asenbauer H, Klobeck G, Polack A, 
Bornkamm GW. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in 
Burkitt’s lymphoma. Oncogene. 1999; 18:1745–1753. [PubMed: 10208435] 
19. Robbiani DF, Nussenzweig MC. Chromosome translocation, B cell lymphoma, and activation-
induced cytidine deaminase. Annual review of pathology. 2013; 8:79–103.
20. Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkandawire N, Liomba G, Batumba 
M, Lagos D, Gratrix F, Boshoff C, Casabonne D, Carpenter LM, Newton R. Associations between 
Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results 
from a case-control study. PLoS One. 2008; 3:e2505. [PubMed: 18560562] 
21. Rasti N, Falk KI, Donati D, Gyan BA, Goka BQ, Troye-Blomberg M, Akanmori BD, Kurtzhals 
JA, Dodoo D, Consolini R, Linde A, Wahlgren M, Bejarano MT. Circulating epstein-barr virus in 
God et al. Page 15
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
children living in malaria-endemic areas. Scand J Immunol. 2005; 61:461–465. [PubMed: 
15882438] 
22. Njie R, Bell AI, Jia H, Croom-Carter D, Chaganti S, Hislop AD, Whittle H, Rickinson AB. The 
effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in 
Gambian children. J Infect Dis. 2009; 199:31–38. [PubMed: 19032105] 
23. Piriou E, Kimmel R, Chelimo K, Middeldorp JM, Odada PS, Ploutz-Snyder R, Moormann AM, 
Rochford R. Serological evidence for long-term Epstein-Barr virus reactivation in children living 
in a holoendemic malaria region of Kenya. J Med Virol. 2009; 81:1088–1093. [PubMed: 
19382256] 
24. Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, Bierman PJ, Bociek RG, Armitage JO. 
Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park). 2008; 
22:1508–1517. [PubMed: 19133605] 
25. Sharipo A, Imreh M, Leonchiks A, Imreh S, Masucci MG. A minimal glycine-alanine repeat 
prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism 
for selective inhibition of proteolysis. Nat Med. 1998; 4:939–944. [PubMed: 9701247] 
26. Fogg MH, Wirth LJ, Posner M, Wang F. Decreased EBNA-1-specific CD8+ T cells in patients 
with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2009; 
106:3318–3323. [PubMed: 19211798] 
27. Lee SP, Brooks JM, Al-Jarrah H, Thomas WA, Haigh TA, Taylor GS, Humme S, Schepers A, 
Hammerschmidt W, Yates JL, Rickinson AB, Blake NW. CD8 T cell recognition of endogenously 
expressed epstein-barr virus nuclear antigen 1. The Journal of experimental medicine. 2004; 
199:1409–1420. [PubMed: 15148339] 
28. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D. Loss of EBNA1-
specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related 
non-Hodgkin lymphoma. Blood. 2005; 106:3166–3174. [PubMed: 16014568] 
29. Schlee M, Schuhmacher M, Holzel M, Laux G, Bornkamm GW. c-MYC impairs immunogenicity 
of human B cells. Advances in cancer research. 2007; 97:167–188. [PubMed: 17419945] 
30. Aubert RD, Kamphorst AO, Sarkar S, Vezys V, Ha SJ, Barber DL, Ye L, Sharpe AH, Freeman GJ, 
Ahmed R. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral 
infection. Proc Natl Acad Sci U S A. 2011; 108:21182–21187. [PubMed: 22160724] 
31. Fu T, Voo KS, Wang RF. Critical role of EBNA1-specific CD4+ T cells in the control of mouse 
Burkitt lymphoma in vivo. J Clin Invest. 2004; 114:542–550. [PubMed: 15314691] 
32. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-
cell responses during chronic viral infection. J Virol. 1994; 68:8056–8063. [PubMed: 7966595] 
33. Paludan C, Bickham K, Nikiforow S, Tsang ML, Goodman K, Hanekom WA, Fonteneau JF, 
Stevanovic S, Munz C. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt’s 
lymphoma cells. Journal of immunology. 2002; 169:1593–1603.
34. Khanna R, Burrows SR, Steigerwald-Mullen PM, Moss DJ, Kurilla MG, Cooper L. Targeting 
Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune 
recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent 
processing. Int Immunol. 1997; 9:1537–1543. [PubMed: 9352359] 
35. Khanna R, Burrows SR, Thomson SA, Moss DJ, Cresswell P, Poulsen LM, Cooper L. Class I 
processing-defective Burkitt’s lymphoma cells are recognized efficiently by CD4+ EBV-specific 
CTLs. Journal of immunology. 1997; 158:3619–3625.
36. Long HM, Zuo J, Leese AM, Gudgeon NH, Jia H, Taylor GS, Rickinson AB. CD4+ T-cell clones 
recognizing human lymphoma-associated antigens: generation by in vitro stimulation with 
autologous Epstein-Barr virus-transformed B cells. Blood. 2009; 114:807–815. [PubMed: 
19443664] 
37. Saito N, Courtois G, Chiba A, Yamamoto N, Nitta T, Hironaka N, Rowe M, Yamamoto N, 
Yamaoka S. Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane 
protein 1 activate NF-kappaB through distinct signaling pathways in fibroblast cell lines. The 
Journal of biological chemistry. 2003; 278:46565–46575. [PubMed: 12968033] 
God et al. Page 16
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
38. Staege MS, Lee SP, Frisan T, Mautner J, Scholz S, Pajic A, Rickinson AB, Masucci MG, Polack 
A, Bornkamm GW. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr 
virus-infected B cells. Proc Natl Acad Sci U S A. 2002; 99:4550–4555. [PubMed: 11917131] 
39. Chornoguz O, Gapeev A, O’Neill MC, Ostrand-Rosenberg S. Major histocompatibility complex 
class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-
specific T cells from breast cancer patients. Molecular & cellular proteomics: MCP. 2012; 
11:1457–1467. [PubMed: 22942358] 
40. Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S. The 
absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive 
type 1 CD4+ T lymphocytes. Cancer immunology, immunotherapy: CII. 2008; 57:389–398.
41. God JM, Zhao D, Cameron CA, Amria S, Bethard JR, Haque A. Disruption of HLA class II 
antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in 
CD4+ T-cell recognition. Immunology. 2014; 142:492–505. [PubMed: 24628049] 
42. Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart JW, Kremmer E, Delecluse HJ, Rottenberger C, 
Bornkamm GW, Hammerschmidt W. B-cell proliferation and induction of early G1-regulating 
proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 1995; 14:88–96. 
[PubMed: 7828599] 
43. Amria S, Cameron C, Stuart R, Haque A. Defects in HLA class II antigen presentation in B-cell 
lymphomas. Leuk Lymphoma. 2008; 49:353–355. [PubMed: 18231926] 
44. Balkan W, Martinez AF, Fernandez I, Rodriguez MA, Pang M, Troen BR. Identification of NFAT 
binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand. Gene. 
2009; 446:90–98. [PubMed: 19563866] 
45. Polack A, Hortnagel K, Pajic A, Christoph B, Baier B, Falk M, Mautner J, Geltinger C, Bornkamm 
GW, Kempkes B. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed 
cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proceedings of the 
National Academy of Sciences of the United States of America. 1996; 93:10411–10416. [PubMed: 
8816814] 
46. Radwan FF, Zhang L, Hossain A, Doonan BP, God JM, Haque A. Mechanisms regulating 
enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell 
lymphoma by resveratrol. Leuk Lymphoma. 2012; 53:305–314. [PubMed: 21854084] 
47. Haque MA, Li P, Jackson SK, Zarour HM, Hawes JW, Phan UT, Maric M, Cresswell P, Blum JS. 
Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell 
recognition of select immunodominant epitopes. The Journal of experimental medicine. 2002; 
195:1267–1277. [PubMed: 12021307] 
48. Ma C, Whiteley PE, Cameron PM, Freed DC, Pressey A, Chen SL, Garni-Wagner B, Fang C, 
Zaller DM, Wicker LS, Blum JS. Role of APC in the selection of immunodominant T cell 
epitopes. J Immunol. 1999; 163:6413–6423. [PubMed: 10586031] 
49. Pathak SS, Blum JS. Endocytic recycling is required for the presentation of an exogenous peptide 
via MHC class II molecules. Traffic. 2000; 1:561–569. [PubMed: 11208144] 
50. Hossain A, God JM, Radwan FF, Amria S, Zhao D, Bethard JR, Haque A. HLA class II defects in 
Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition. Clin 
Dev Immunol. 2011; 2011:780839. [PubMed: 22162713] 
51. Li P, Haque MA, Blum JS. Role of disulfide bonds in regulating antigen processing and epitope 
selection. J Immunol. 2002; 169:2444–2450. [PubMed: 12193713] 
52. Zhao D, Amria S, Hossain A, Sundaram K, Komlosi P, Nagarkatti M, Haque A. Enhancement of 
HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment 
with bryostatin-1. Cell Immunol. 2011; 271:392–400. [PubMed: 21903207] 
53. Hossain A, Radwan FF, Doonan BP, God JM, Zhang L, Bell PD, Haque A. A possible cross-talk 
between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis: an 
international journal on programmed cell death. 2012; 17:1066–1078. [PubMed: 22847295] 
54. Younger AR, Amria S, Jeffrey WA, Mahdy AE, Goldstein OG, Norris JS, Haque A. HLA class II 
antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis. 2008; 11:334–341. 
[PubMed: 17938645] 
God et al. Page 17
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
55. Haque A, Das A, Hajiaghamohseni LM, Younger A, Banik NL, Ray SK. Induction of apoptosis 
and immune response by all-trans retinoic acid plus interferon-gamma in human malignant 
glioblastoma T98G and U87MG cells. Cancer Immunol Immunother. 2007; 56:615–625. 
[PubMed: 16947022] 
56. Goldstein OG, Hajiaghamohseni LM, Amria S, Sundaram K, Reddy SV, Haque A. Gamma-IFN-
inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen 
processing in melanoma. Cancer Immunol Immunother. 2008; 57:1461–1470. [PubMed: 
18343923] 
57. Amria S, Hajiaghamohseni LM, Harbeson C, Zhao D, Goldstein O, Blum JS, Haque A. HLA-DM 
negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell 
recognition. Eur J Immunol. 2008; 38:1961–1970. [PubMed: 18506881] 
58. Rothbard JB, Busch R, Howland K, Bal V, Fenton C, Taylor WR, Lamb JR. Structural analysis of 
a peptide--HLA class II complex: identification of critical interactions for its formation and 
recognition by T cell receptor. International immunology. 1989; 1:479–486. [PubMed: 2489038] 
59. Zhang S, Zhang H, Zhao J. The role of CD4 T cell help for CD8 CTL activation. Biochem Biophys 
Res Commun. 2009; 384:405–408. [PubMed: 19410556] 
60. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. 
Annu Rev Immunol. 2006; 24:519–540. [PubMed: 16551258] 
61. Khanolkar A, Badovinac VP, Harty JT. CD8 T cell memory development: CD4 T cell help is 
appreciated. Immunol Res. 2007; 39:94–104. [PubMed: 17917058] 
62. Pajic A, Staege MS, Dudziak D, Schuhmacher M, Spitkovsky D, Eissner G, Brielmeier M, Polack 
A, Bornkamm GW. Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the 
phenotype of human B cells. Int J Cancer. 2001; 93:810–816. [PubMed: 11519042] 
63. Pajic A, Polack A, Staege MS, Spitkovsky D, Baier B, Bornkamm GW, Laux G. Elevated 
expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I 
switch. J Gen Virol. 2001; 82:3051–3055. [PubMed: 11714983] 
64. Schlee M, Holzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic 
D, Wirth T, Rosenwald A, Staudt LM, Eilers M, Baran-Marszak F, Fagard R, Feuillard J, Laux G, 
Bornkamm GW. C-myc activation impairs the NF-kappaB and the interferon response: 
implications for the pathogenesis of Burkitt’s lymphoma. International journal of cancer. Journal 
international du cancer. 2007; 120:1387–1395. [PubMed: 17211884] 
65. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, 
induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. 
Exp Hematol. 2006; 34:1480–1489. [PubMed: 17046567] 
66. Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. 
EMBO J. 2008; 27:1–5. [PubMed: 18046453] 
67. Haque A, Blum JS. New insights in antigen processing and epitope selection: development of 
novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases. J Biol Regul 
Homeost Agents. 2005; 19:93–104. [PubMed: 16602623] 
68. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013; 
31:443–473. [PubMed: 23298205] 
69. Gras S, Burrows SR, Turner SJ, Sewell AK, McCluskey J, Rossjohn J. A structural voyage toward 
an understanding of the MHC-I-restricted immune response: lessons learned and much to be 
learned. Immunol Rev. 2012; 250:61–81. [PubMed: 23046123] 
70. West LC, Cresswell P. Expanding roles for GILT in immunity. Curr Opin Immunol. 2013; 25:103–
108. [PubMed: 23246037] 
71. Norton DL, Haque A. Insights into the Role of GILT in HLA Class II Antigen Processing and 
Presentation by Melanoma. J Oncol. 2009; 2009:142959. [PubMed: 20016802] 
72. Stern LJ, Potolicchio I, Santambrogio L. MHC class II compartment subtypes: structure and 
function. Curr Opin Immunol. 2006; 18:64–69. [PubMed: 16337363] 
73. Landsverk OJ, Bakke O, Gregers TF. MHC II and the endocytic pathway: regulation by invariant 
chain. Scand J Immunol. 2009; 70:184–193. [PubMed: 19703008] 
God et al. Page 18
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
74. Chen X, Jensen PE. MHC class II antigen presentation and immunological abnormalities due to 
deficiency of MHC class II and its associated genes. Exp Mol Pathol. 2008; 85:40–44. [PubMed: 
18547561] 
75. Painter CA, Stern LJ. Conformational variation in structures of classical and non-classical MHCII 
proteins and functional implications. Immunol Rev. 2012; 250:144–157. [PubMed: 23046127] 
76. Denzin LK, Fallas JL, Prendes M, Yi W. Right place, right time, right peptide: DO keeps DM 
focused. Immunol Rev. 2005; 207:279–292. [PubMed: 16181343] 
77. Martin R, Olivares M, Perez M, Xaus J, Torre C, Fernandez L, Rodriguez JM. Identification and 
evaluation of the probiotic potential of lactobacilli isolated from canine milk. Veterinary journal. 
2010; 185:193–198.
78. Busch R, Rinderknecht CH, Roh S, Lee AW, Harding JJ, Burster T, Hornell TM, Mellins ED. 
Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding 
and expression. Immunol Rev. 2005; 207:242–260. [PubMed: 16181341] 
79. Morris P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, Monaco JJ, Mellins E. An 
essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. 
Nature. 1994; 368:551–554. [PubMed: 8139689] 
80. Guce AI, Mortimer SE, Yoon T, Painter CA, Jiang W, Mellins ED, Stern LJ. HLA-DO acts as a 
substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol. 2013; 
20:90–98. [PubMed: 23222639] 
81. Chen X, Jensen PE. The expression of HLA-DO (H2-O) in B lymphocytes. Immunol Res. 2004; 
29:19–28. [PubMed: 15181267] 
82. Xiu F, Cote MH, Bourgeois-Daigneault MC, Brunet A, Gauvreau ME, Shaw A, Thibodeau J. 
Cutting edge: HLA-DO impairs the incorporation of HLA-DM into exosomes. J Immunol. 2011; 
187:1547–1551. [PubMed: 21768396] 
83. Glazier KS, Hake SB, Tobin HM, Chadburn A, Schattner EJ, Denzin LK. Germinal center B cells 
regulate their capability to present antigen by modulation of HLA-DO. J Exp Med. 2002; 
195:1063–1069. [PubMed: 11956297] 
84. Pathak SS, Lich JD, Blum JS. Cutting edge: editing of recycling class II:peptide complexes by 
HLA-DM. Journal of immunology. 2001; 167:632–635.
85. Haque MA, Hawes JW, Blum JS. Cysteinylation of MHC class II ligands: peptide endocytosis and 
reduction within APC influences T cell recognition. Journal of immunology. 2001; 166:4543–
4551.
86. Yin L, Trenh P, Guce A, Wieczorek M, Lange S, Sticht J, Jiang W, Bylsma M, Mellins ED, 
Freund C, Stern LJ. Susceptibility to HLA-DM protein is determined by a dynamic conformation 
of major histocompatibility complex class II molecule bound with peptide. The Journal of 
biological chemistry. 2014; 289:23449–23464. [PubMed: 25002586] 
87. Phipps-Yonas H, Semik V, Hastings KT. GILT expression in B cells diminishes cathepsin S 
steady-state protein expression and activity. Eur J Immunol. 2013; 43:65–74. [PubMed: 23012103] 
88. Maric M, Arunachalam B, Phan UT, Dong C, Garrett WS, Cannon KS, Alfonso C, Karlsson L, 
Flavell RA, Cresswell P. Defective antigen processing in GILT-free mice. Science. 2001; 
294:1361–1365. [PubMed: 11701933] 
89. O’Donnell PW, Haque A, Klemsz MJ, Kaplan MH, Blum JS. Cutting edge: induction of the 
antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is 
STAT1-dependent but CIITA-independent. Journal of immunology. 2004; 173:731–735.
90. Denzin LK, Cresswell P. Sibling rivalry: competition between MHC class II family members 
inhibits immunity. Nat Struct Mol Biol. 2013; 20:7–10. [PubMed: 23288359] 
91. God JM, Zhao D, Cameron CA, Amria S, Bethard JR, Haque A. Disruption of HLA class II 
antigen presentation in Burkitt lymphoma: implication of a 47 000 MW acid labile protein in 
CD4(+) T-cell recognition. Immunology. 2014; 142:492–505. [PubMed: 24628049] 
92. Subramanian A, Miller DM. Structural analysis of alpha-enolase. Mapping the functional domains 
involved in down-regulation of the c-myc protooncogene. The Journal of biological chemistry. 
2000; 275:5958–5965. [PubMed: 10681589] 
God et al. Page 19
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
93. Sedoris KC, Thomas SD, Miller DM. c-myc promoter binding protein regulates the cellular 
response to an altered glucose concentration. Biochemistry. 2007; 46:8659–8668. [PubMed: 
17595061] 
God et al. Page 20
J Immunol. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. 
Overexpression of c-MYC imparts a non-immunogenic BL phenotype to B-LCL and 
diminishes HLA-DR4-mediated CD4+ T cell recognition of BL-type cells. A, The wild-type 
B-cell line Frev which constitutively expresses HLA-DR4 molecules was either transfected 
with an empty vector or c-myc by electroporation. EREB2-5 cells are immortalized by EBV 
expressing a conditional estrogen receptor EBNA2 fusion protein (EREBNA2), and cellular 
proliferation is dependent on the availability of estrogen. A1 was established by stable 
transfection of conditionally EBV immortalized EREB2-5 cells with a c-myc/Igκ expression 
plasmid. The B-LCL-type cell line EREB2-5 and its derivative A1 (BL-type) were 
retrovirally transduced with HLA-DR4. Frev.vec, Frev.c-myc, EREB2-5.DR4 and A1.DR4 
cells were then analyzed by western blotting for c-MYC, EBNA1, and EBNA2 proteins as 
described in the methods. β-actin was used as a loading control. B, Cells were subjected to 
microscopy for analysis of morphological characteristics (magnification × 20). C, Cells were 
stained for surface HLA-DR4 molecules using 359-F10 antibody and matched isotype 
control (IN-1), and analyzed by a flow cytometer as described. D, For T cell recognition 
assay, cells were incubated with different concentrations (0, 5, 10, 20μM) of a synthetic 
HSA64-76K peptide for 4h, washed and cocultured with the peptide-specific T cell 
hybridoma (17.9) for 24h. T cell production of IL-2 in the culture supernatant was 
quantitated by ELISA and expressed as pg/ml±SEM. Data are representative of three 
separate experiments.
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Figure 2. 
Overexpression of c-MYC minimally influences HLA class II and Ii proteins, but alters 
other components of the class II pathway. A, B-LCL-type cells (Frev.vec and 
EREB2-5.DR4) and BL-type cells (Frev.c-myc and A1.DR4) were analyzed by western 
blotting for the expression of HLA-DR (L243), Ii (Pin 1.1), peptide editor HLA-DM and 
lysosomal thiol-reductase GILT (Santa Cruz antibodies) proteins. β-actin was used as a 
loading control. B, Densitometric analysis of protein bands detected in Figure 2A. Data are 
average density of three independent measurements of a representative band image and 
expressed as relative density (protein band/actin) ± S.D. Significant differences in relative 
band intensity were calculated by the Wilcoxon Rank Sum test; *p ≤0.0022. C, Flow 
cytometric analysis showing percent cell surface class II DR protein expression in BL (c-
mychigh) and B-LCL (c-myclow) type cells. Frev.vec, Frev.c-myc, EREB2-5.DR4, and 
A1.DR4 cells were stained with an antibody against HLA-DR (L243), and a matched 
isotype (NN4) control, followed by flow cytometric analysis.
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Figure 3. 
Overexpression of c-MYC disrupts both exogenous and endogenous presentation of Ags to 
T cells via the HLA class II pathway. A, Western blot analysis of c-MYC protein levels in 
B-LCL and BL-type cells. HLA-DR4-transfected B-LCL-type cells (6.16.DR4.DM) and 
BL-type cells (Nalm.DR4, Ramos.DR4) were subjected to western blotting for determining 
the levels of c-MYC proteins. β-actin was used as a loading control. B, left panel: processing 
and presentation of natural epitopes from an exogenous Ag (Igκ). B, right panel: 
presentation of the synthetic forms of Igκ epitopes. Cells (6.16.DR4.DM, Nalm.DR4, and 
Ramos.DR4) were incubated with either whole Igκ (left panel) or synthetic epitopes 
(κ188-203 and κ145-159 peptides) (right panel) for 4h. Following incubation, cells were 
washed and co-cultured with the appropriate epitope or peptide specific T cell hybridomas 
(2.18a for κ188-203 and 1.21 for κ145-159) for 24h. Supernatants obtained from the co-culture 
assay were tested by ELISA to determine IL-2 levels as a measure of T-cell stimulation. T 
cell production of IL-2 was quantitated and expressed as pg/ml. C, Western blot analysis 
showing c-MYC protein expression in B-LCL (Priess), BL-type (A1.DR4) and B-LCL-type 
cells (EREB2-5.DR4). D, left panel (exogenous presentation): EREB2-5.DR4, A1.DR4 and 
Priess cells were incubated with a whole Ag HSA for 4h, followed by coculture with the 
HSA64-76K peptide specific T cell hybridoma (17.9) for 24h. D, right panel (endogenous 
presentation): EREB2-5.DR4, A1.DR4 and Priess cells express endogenous Igκ. While 
EREB2-5.DR4 and A1.DR4 cells are transduced with DR4, Priess cells are homozygous for 
DR4 alleles. These cells were cocultured with the HLA-DR4-restricted Igκ188-203 and 
Igκ145-159 peptide specific T cell hybridomas (2.18a for Igκ188-203 and 1.21 for Igκ145-159 
respectively) in the absence of exogenous Ag, for 24h. T cell production of IL-2 was 
quantitated by ELISA and expressed as pg/ml±SEM. Data are representative of three 
separate experiments.
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Figure 4. 
Shift from a LCL- to a BL-like phenotype in P493-6 cells did not alter HLA class II protein 
expression, but decreased CD4+ T cell recognition via both exogenous and endogenous 
pathway of HLA class II Ag presentation. A, P493-6 cells were reversibly shifted from a 
LCL- to a BL-like phenotype by withdrawal and re-addition of estrogen (2μM) plus 
tetracycline (5μg/ml). Western blot analysis of P493-6.DR4 cells for c-MYC protein 
expression under c-myclow (est/tet) and c-mychigh (no est/tet) culture conditions. β-actin was 
used as a loading control. B, Flow cytometric analysis of surface HLA-DR (antibody L243) 
and HLA-DR4 (antibody 359-F10) molecules in c-myclow (B-LCL) and c-mychigh (BL-like) 
cells. C, Ag presentation assay showing exogenous presentation of HSA Ag/peptide. 
P493-6.DR4 cells were first cultured under c-mychigh (P493-6.DR4, without est/tet) and c-
myclow (P493-6DR4, with est/tet) conditions, and then incubated with the whole HSA or 
HSA64-76K peptide for 4h, followed by coculture with the HSA64-76K peptide specific T cell 
hybridoma (17.9) for 24h. D, Ag presentation assay showing endogenous presentation of 
Igκ. P493-6.DR4 cells grown under c-mychigh (P493-6.DR4, without est/tet) and c-myclow 
(P493-6DR4, with est/tet) conditions were cocultured with the HLA-DR4-restricted 
Igκ188-203 and Igκ145-159 peptide specific T cell hybridomas (2.18a for Igκ188-203 and 1.21 
for Igκ145-159 respectively) in the absence of exogenous Ag, for 24h. Supernatants obtained 
from these T cell assays were tested by ELISA to determine IL-2 levels as a measure of T-
cell stimulation. T cell production of IL-2 was expressed as mean pg/ml±SEM. E, Peptide 
binding assay at 4°C. P493-6.DR4 cells grown under c-mychigh (P493-6.DR4, without est/
tet) and c-myclow (P493-6DR4, with est/tet) conditions were incubated with vehicle alone or 
biotin-labeled HSA64-76K peptide for 24h. F, Peptide binding assay at 37°C. Cells 
(P493-6.DR4) grown under c-mychigh and c-myclow conditions, washed and fixed with 1% 
paraformaldehyde, and were incubated with biotin-labeled HSA64-76K peptide for 24, 
followed by staining with FITC-avidin. After washing, cells were analyzed by flow 
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cytometry as described in the methods. Data are representative of three separate 
experiments.
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Figure 5. 
Treatment with the c-MYC inhibitor 10058-F4 partially restored CD4+ T cell recognition of 
c-MYC overexpressing P493-6 cells via the HLA class II pathway. P493-6 cells were grown 
in complete RPMI1640 medium in the absence of estrogen and tetracycline (BL-like 
phenotype). A, Expression of c-MYC proteins in P493-6 cells treated with various 
concentrations (0, 50 and 100μM) of the c-MYC inhibitor 10058-F4 for 24h. Cells were then 
washed and subjected to western blotting for analyzing c-MYC protein expression. β-actin 
was used as a loading control. B, left panel: P493-6 cells were cultured in the presence or 
absence of c-MYC inhibitor 10058-F4 (50μM) for 24h, followed by the addition of whole 
HSA or HSA64-76K peptide (10 μM) for the last 4h of incubation. Cells were washed, fixed 
with 1% paraformaldehyde, and cocultured with the HSA64-76K peptide specific T cell 
hybridoma (17.9) for 24h. T cell production of IL-2 in the culture supernatant was 
quantitated by ELISA and expressed as mean pg/ml±SEM. B, right panel: A1.DR4 and 
P493-6.DR4 cells which express endogenous Igκ were cultured in the presence or absence 
of c-MYC inhibitor 10058-F4 (50μM) for 24h. Cells were washed, fixed with 1% 
paraformaldehyde, and cocultured with the HLA-DR4-restricted Igκ188-203 peptide specific 
T cell hybridoma (2.18a) for 24h. Supernatants obtained were tested by ELISA to determine 
IL-2 levels as a measure of T-cell proliferation. Data are representative of three separate 
experiments. *p<0.05. C, Flow cytometric analysis of P493-6 cells treated with the c-MYC 
inhibitor 10058-F4 for 24h. Cells were first treated with 10058-F4 and stained with an 
antibody against CLIP (Cer-CLIP antibody) plus a matched isotype control (NN4 antibody) 
for determining surface CLIP protein expression (upper panel). Cells treated with 10058-F4 
were also subjected to intracellular staining with antibodies against HLA-DM and HLA-DO 
molecules as described in the methods. The lower panel shows the effect of c-MYC inhibitor 
10058-F4 on differential expression of HLA-DM and HLA-DO proteins in P493-6 cells as 
compared to untreated controls.
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Figure 6. 
Overexpression of c-MYC alters cell surface CLIP by regulating DM/DO ratio in BL/B-
LCL type cells. A, DR4 expressing P493-6 cells were cultured under c-myc-on 
[(P493-6.DR4)(minus estrogen, minus tetracycline)] and c-myc-off conditions 
[(P493-6.DR4.est.tet)(plus estrogen, plus tetracycline). Cells were then intracellularly 
stained with antibody against Ii (Pin1.1), followed by addition of FITC-labeled secondary 
antibody as described. Cells were also stained with cer-CLIP antibody for cell surface CLIP 
proteins and analyzed by flow cytometry. B, P493-6 cells grown under c-myc-on and c-myc-
off conditions were also intracellularly stained with antibodies against HLA-DM/HLA-DO 
proteins and appropriate isotype controls, followed by flow cytometric analysis. C, Bar 
graphs showing mean fluorescence intensity ±SEM of HLA-DM and HLA-DO staining in 
P493-6.DR4 and P493-6.DR4.est.tet cells. Data are representative of at least three separate 
experiments. *p<0.001. D, Analysis of a 47kDa protein differentially expressed in BL- vs B-
LCL-type cells. Acid eluates obtained from BL-type (P493-6.DR4) and B-LCL-type 
(P493-6.DR4.est.tet) cells were separated and detected on a non-reducing gel as described in 
the methods. An approximately 47kDa band was excised and analyzed by MALDI-
TOF/TOF mass spectrometry. Data shown are representative of at three separate 
experiments.
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Figure 7. High CLIP expression, a decrease in the DM/DO ratio, and impaired MHC class II 
antigen presentation, are also observed in BL tumors ex vivo
A, Human primary BL (TB#2952) cells were isolated from lymph node samples obtained 
from lymphoma patients as described in the methods. This primary BL tumor as well as 
control B-cells from a healthy individual (C#16) were analyzed by western blotting for c-
MYC, class II protein expression, and HSA64-76K peptide presentation. In parallel, these B 
cell tumors and control B-cells were also transduced with DR4β as described. B, HLA-
DR4β-transduced early passage TB#2952 tumor cells were either directly tested for 
HSA64-76K peptide presentation or infected in vitro with EBV [TB#2952(+EBV)] and then 
used in the T cell assay as described in Figure 1D. Healthy B-cells (C#16) infected in vitro 
with EBV [C#16(+EBV)] were also tested in the T cell assay for CD4+ T cell recognition, 
and the data were compared with those of the tumors. Black bars, DR4β-transduced after 
EBV infection; white bars, DR4β-transduced without EBV infection; grey bars, DR4β-
transduced after EBV infection. C, B-cells from healthy individuals (C#16, C#101) and 
primary BL tumors (TB#2952 and TB#7378) were stained with antibodies against HLA-DR, 
CLIP and HLA-DM/DO proteins plus appropriate secondary antibodies and matched isotype 
controls (red) as described in the methods. Cells were then analyzed by flow cytometry.
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Table I
Cell lines used in this study:
Cell name(s) Cell type(s)
HLA-DR4 expression
Reference(s)
Constitutive Transduced
Frev B-lymphoblastoid cell Yes No 41
Priess B-lymphoblastoid cell Yes No 41
Nalm-6.DR4 Lymphocytic leukemia cell line No Yes 41, 46
Ramos.DR4 Burkitt lymphoma cell No Yes 41, 46
6.16.DR4.DM B-lymphoblastoid cell line No Yes 41, 46
REEB2-5.DR4 B-lymphoblast type cell line No Yes 38, 42
A1.DR4 Burkitt lymphoma type cell line No Yes 38, 42
P493-6.DR4 Burkitt lymphoma type cell line No Yes 38, 42
TB#2952 Early passage Burkitt lymphoma No Yes 43
TB#7378 Early passage Burkitt lymphoma No Yes Unpublished
C#16 Early passage B cells No Yes Unpublished
C#101 Early passage B cells No Yes Unpublished
2.18a T cell hybridoma against Igκ188-203 -- -- 41, 47
1.21 T cell hybridoma against Igκ145-159 -- -- 41, 47
17.9 T cell hybridoma against HSA64-76K -- -- 41, 53
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